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Abstract
Cell therapies are becoming increasingly widely used, and their production and cryopreserva-
tion should take place under tightly controlled GMP conditions, with minimal batch-to-batch
variation. One potential source of variation is in the thawing of cryopreserved samples, typi-
cally carried out in water baths. This study looks at an alternative, dry thawing, to minimise
variability in the thawing of a cryopreserved cell therapy, and compares the cellular outcome
on thaw. Factors such as storage time, patient age, and gender are considered in terms of
cryopreservation and thawing outcomes. Cryopreserved leukapheresis samples from 41
donors, frozen by the same protocol and stored for up to 17 years, have been thawed using
automated, water-free equipment and by conventional wet thawing using a water bath. Post-
thaw viability, assessed by both trypan blue and flow cytometry, showed no significant differ-
ences between the techniques. Similarly, there was no negative effect of the duration of fro-
zen storage, donor age at sample collection or donor gender on post-thaw viability using
either thawing method. The implication of these results is that the cryopreservation protocol
chosen initially remains robust and appropriate for use with a wide range of donors. The posi-
tive response of the samples to water-free thawing offers potential benefits for clinical situa-
tions by removing the subjective element inherent in water bath thawing and eliminating
possible contamination issues.
Introduction
The use of cell therapies such as CAR T cells as an effective treatment for a range of conditions
is growing rapidly, harnessing the power of the immune system to fight cancers [1]. Sourcing
the initial biological sample to create the preparation used for treatment is the first, key ele-
ment in this process. For blood-based therapies this is commonly taken from cord blood, or
an apheresis sample, for autologous treatments or allografts [2]. The initial sample may be
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minimally manipulated e.g. by apheresis or may become the starting point of a more complex
manufacturing process to provide the final therapeutic material, a common feature of CAR T
treatments [3].
The processes for transforming an initial sample into completed cell materials, and inevita-
ble uncertainties over the time and place of delivery to the patient, makes effective storage an
essential, enabling element in effective treatment [4]. Cryopreservation offers stable, extended
storage and samples can be cryopreserved immediately after extraction e.g. for cord blood and
then stored in a cell bank until required [5]. Additional processing of an initial sample can also
take place before cryopreservation e.g. leukapheresis of sample from patients in remission
from myeloma or non-Hodgkin’s lymphoma, for use if the patient relapses.
Cryopreservation has three key phases, notably cooling, storage and thawing [4,6]. For clini-
cal cell systems, beyond the research laboratory, the first two of these are precisely controlled
and recorded using validated protocols and automated controlled-rate freezers. Automatic
alarms and monitoring systems are essential for good storage practice in frozen tissue banks
[7]. Efficient thawing, with minimal reduction in viability and performance is essential before
further processing and is often the final manipulation of a completed product carried out at the
point of delivery to the patient. Clearly, any errors in thawing that damage the product, however
they are caused, could have damaging consequences for the effectiveness of the cell therapy.
Thawing of cryopreserved materials has developed, over time, as a relatively simple pro-
cedure with a strong, subjective element. Typically, this involves the immersion of the frozen
sample in a water bath at 37˚C with melting of the last ice visually determined (wet thawing).
Different operators may choose a slightly different end-of-thaw indicator, with samples e.g.
cryobags, held at different angles or agitated at different speeds (or not at all). This com-
pounds the risk of user-to-user variability producing variable results. It is acknowledged
that, in the hands of a specialist technician, the essentially subjective technique of wet thaw-
ing is successful and, largely, consistent. However, the end-user of a cryopreserved product
can be separated by location and time from the specialists that processed and froze the initial
material. Consequently, thawing is increasingly carried out, often at the bedside, by clinical
staff who may have little, or no, training or experience in cryopreservation. This generates a
real risk of mishandling that can reduce post-transplant performance, due to a reduction in
viable cell number.
Whilst practicable in a research laboratory, thawing water baths can also create a contam-
ination risk that is unacceptable in many clinical situations [8–10]. Additional time and
facilities for sterilisation, rewarming, refilling and temperature stabilisation must also be
available. Recently, however, variants of equipment that enable water-free thawing of larger
samples, held in cryobags, are becoming available. These systems use mechanical heating,
such as a warm metallic plate as used in this study and/or warmed but sealed liquids that do
not come into direct contact with the sample being thawed [11–15]. These systems eliminate
user-to-user variability and provide a consistent, programmable process that removes any
subjective intervention on the part of the user. They also provide options for computerised
control, monitoring and data recording. Previous studies have also indicated that dry thaw-
ing can be applied successfully to non-cellular therapeutic materials such as plasma samples
[11–13,15], however as water is fluid and a very effective thermal conductor, these typically
have slightly longer warming times than a water bath-based system.
Patients selected for apheresis, including leukapheresis, for myeloma therapy, will show
innate, individual variation in responses to mobilization possibly due to age, health condi-
tion or gender [16,17]. To provide therapy, using cryopreserved material, at an optimal level
it is essential to understand how this variation may influence the post-thaw performance of
thawed cell preparations. Any further increase in variation that could be caused by poor
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control within the cryopreservation process has to be minimised. This is particularly rele-
vant to thawing for the reasons outlined above.
The availability of cryopreserved leukapheresis samples destined for disposal (taken from
donors who had been successfully treated for myeloma and were in remission), provided a
unique opportunity to compare and review the post-thaw performance of samples that had
been stored, using the same protocol, for as long as 17 years. The protocol used was able to cryo-
preserve the 2x106 viable cells kg-1 (measured pre-cryopreservation) of recipient body weight in
most patients deemed necessary for effective therapy [16,17]. The study used paired samples for
up to 41 patients and the influence on post-thaw viability of cryostorage time, patient gender
and age at sample collection was investigated. Additionally, the study compared the effective-
ness of water-free and wet thawing on these samples.
Materials and methods
Cell samples and cryopreservation
Paired leukapheresis samples from male and female patients in remission from myeloma or
non-Hodgkin’s lymphoma, aged between 39 and 70 years old at collection were provided. The
mobilized peripheral blood was prepared by mobilization techniques, which include five daily
injections of filgrastim (G-CSF) and cyclophosphamide to stimulate stem cells out of bone
marrow into the bloodstream.
Apheresis samples were obtained post-discard from the biobank which were no longer
needed for clinical use. Patients previously gave informed consent for cell donations to the
cell bank to be used for research and development if they were no longer required for clinical
treatment.
There were between 60 and 140ml of the completed cell preparation in each cryobag
(CryoStore, CS500NS or CS250NS, Origen Biomedical, Austin, USA). The samples were dou-
ble bagged with an overwrap (Seaborn Laminate Polypropylene Pouch, Moore & Buckle, St
Helens, UK).
The bags had been cooled in a Kryo-10 Planer controlled-rate freezer (Planer, Sudbury,
UK) following a protocol using a classical set of cooling rates for the cryopreservation of hae-
matopoietic stem cells: a 10-minute equilibration at 4˚C in cryoprotectant consisting of 10%
DMSO in 4.5% Human Albumin Serum, followed by a 2˚C min-1 cooling rate down to -30˚C,
raised to 4˚C min-1 [18–21]. Samples were cooled to -100˚C before transfer to the vapour
phase above liquid nitrogen for storage. The cooling profile was recorded for each cryopreser-
vation run. Continuous temperature monitoring was in place to ensure that the samples did
not experience any warming during storage. All sample pairs were cryopreserved from the
same apheresis, during the same cryopreservation run with equal volumes per bag.
Thawing
Prior to thawing, cryobags were directly transferred from the storage vessel into a fully charged
dry shipper (Chart MVE, Ball Ground, GA, USA) to facilitate transfer to the thawing labora-
tory. Continuous temperature monitoring was employed during transfer to ensure the integrity
of the cryochain. A pair of bags from the same patient extraction were thawed concurrently,
one in a standard laboratory water bath (wet thawing), and the other in a water-free system.
The post-thaw tests on each pair of bags were also carried out concurrently.
To wet thaw, a 16-litre non-circulating water bath with thermostatic temperature control was
freshly filled with water less than 1h before each event and was monitored as being within 1˚C
of 37˚C before use. The temperature was monitored with type T thermocouples connected to a
TC-08 temperature measuring unit (Picotechnology, St. Neots, UK). A cryobag was removed
PLOS ONE Factors impacting storage and thawing of haematopoietic cells: Storage time, age, gender, and wet/dry thawing
PLOS ONE | https://doi.org/10.1371/journal.pone.0240310 October 26, 2020 3 / 12
from the dry shipper and immediately fully submerged in the water bath, where it was gently
agitated. As the last of the visible ice melted the cryobag was removed from the water bath and
post-thaw analysis began immediately. The duration of the thawing episode was recorded.
For water-free thawing, a controlled-rate thawing station (VIA Thaw, Cytiva, Cambridge,
UK) was programmed with the cryobag volume and warmed to 34˚C before the thawing cycle
was started. This system uses adaptable metal plates heated to a set temperature (34˚C) to
warm a cryobag from both sides. Upon removal from the dry shipper the cryobag was immedi-
ately placed into the machine and thawing initiated immediately. When completion of thawing
was indicated, the cryobag was removed and post-thaw analysis started. The duration of the
thawing episode was recorded.
Post-thaw analysis of cryopreserved leukapheresis samples
Trypan blue staining. Cell samples were diluted in trypan blue solution (0.4% trypan
blue in 0.9% saline solution, Sigma, Gillingham, UK #T8154), gently agitated and left to stand
for 1 minute. Thereafter, sample-blind live/dead cell counts were carried out using a haemo-
cytometer with a minimum of at least 100 nucleated cells counted per sample. Where neces-
sary the cell suspensions were further diluted in Hanks Balanced Salt Solution (HBSS,
HyClone, Cytiva, Cramlington, UK #SH30031.03).
Cells that excluded the trypan blue dye were accepted as having an intact, outer membrane
and defined as viable. Those cells with the intracellular volume stained blue were accepted as
having a compromised membrane and were defined as non-viable. Trypan blue viability was
calculated as the percentage of the cell population with an intact cell membrane.
Total nucleated cell count. Total nucleated cells in a 1ml sample of thawed cell prepara-
tion were counted immediately post-thaw using an automated H500 cell counter (Yumizen
H1500, Horiba, Kyoto, Japan).
Colony forming units. A 0.2ml aliquot of cell suspension was placed into 6ml of Metho-
cult gel (Stemcell Technologies, Vancouver, Canada,) and vortexed for 1 minute to allow for
full mixing. Samples were allowed to stand for 5 minutes before 1.1ml was placed into each of
4 wells of a 6-well plate. The plate was incubated at 37˚C in 5% CO2 for 14 days in a humidified
incubator, at which point a colony count was carried out for each well. A colony was defined
as a grouping of approximately 50 or more cells.
Flow cytometry. CD45+, CD34+, and CD34+/7-AAD positive cells were counted by flow
cytometry as a measure of viable cells [22]. Following a total nucleated-cell count, outlined above,
samples were diluted to 1-2x107 cells ml-1 and incubated with CD45 FITC/CD34 PE antibody
(BD Bioscience, Wokingham, Berkshire, UK, #341071) and 7-AAD viability dye (BD Bioscience,
#559925) in BD Trucount tubes (BD Bioscience, #555899) for 15 minutes at room temperature
in the dark. Red cell lysis was performed using Pharmlyse (BD Bioscience, #555899) for 15 min-
utes. Flow cytometric analysis was performed on a minimum of 100,000 total CD45 positive
events using a BD FACSCanto II flow cytometer (BD Bioscience). Absolute live/dead CD45/
CD34 positive cell numbers were determined using a single platform technique with Trucount
beads and an ISHAGE Boolean gating strategy selecting CD45/CD34 positive cells with 7-AAD
live/dead cell determination [23].
Statistical analyses
The R software (versions 3.4.2 and 4.0.2) and R Commander 2.4–1 package were used for sta-
tistical analyses and displaying the data [24,25].
To compare both thawing methods on the measured CD45+ and CD34+ cell post-thaw
recoveries, Bland-Altman analyses were performed, after ensuring the differences between
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both thawing methods for each cellular parameter were normally distributed (Shapiro-Wilk
normality test, p-values = 0.3 and 0.2, respectively).
Linear regressions were used to test for a relationship between post-thaw cellular parameters
and either cryogenic storage time or patient age compared with and Pearson correlation coeffi-
cient. To investigate the influence of gender and thawing method on post-thaw cellular param-
eters, box and whisker plots were drawn. Means were compared with the parametric T-test if
the samples followed a normal distribution and had homogeneous variances (p-values> 0.05)
or with the non-parametric Wilcoxon rank sum test if not (p-values< 0.05).
Results
Thawing method and post-thaw viability of cryopreserved leukapheresis
samples
Analysis of post-thaw cell outcome showed no significant differences (p-values> 0.05) between
water-free and wet thawing (Figs 1 and 2), whether measured as cell viability by the trypan blue
dye exclusion method (Fig 1A), total viable CD34+ cells (Fig 1B) or as colony-forming units
(Fig 1C). The comparison of water-free and wet thawing methods on CD45+ and CD34+ cell
post-thaw viabilities is shown in Fig 2. For CD45+ post-thaw cell viability, the water-free thaw-
ing method gave on average lower results than the wet thawing method with a correlation coef-
ficient of 0.961. On the contrary, for CD34+ post-thaw cell viability, the water-free thawing
method gave on average higher results than the wet thawing method with a correlation coeffi-
cient of 0.834.
Large patient-to-patient variations were observed as is not uncommon in myeloma patients
[16,17] e.g. trypan blue dye exclusion ranged from 38% to 100% and CD34+ viability from 8%
to 87%. Average trypan blue viability was 69.4 ± 19.2%, which was significantly higher than the
CD34+ viability at 49.2 ± 20.4%, (p-value < 0.05). Thawing time was measured as 405 ± 101s
and 337 ± 121s for the water-free and wet thawing respectively (p-value < 0.05).
Storage time and post-thaw survival
Examination of a potential effect of cryogenic storage duration on cell viability, was determined
both as trypan blue dye exclusion and by flow cytometry for CD34+ cells. Considering the com-
bined data for water-free and wet thawed samples (Fig 3), there was no indication of a positive
Fig 1. The comparative effect of water-free and wet thawing on the post-thaw outcome of haematopoietic cells from cryopreserved
leukapheresis samples. (A) Cell viability immediately post-thaw determined as trypan blue exclusion (B) Total CD34+ cell counts (through
flow analysis). (C) Colony forming units counted after 14 days post-thaw incubation. The p-values obtained from comparing means between
thawing methods are indicated.
https://doi.org/10.1371/journal.pone.0240310.g001
PLOS ONE Factors impacting storage and thawing of haematopoietic cells: Storage time, age, gender, and wet/dry thawing
PLOS ONE | https://doi.org/10.1371/journal.pone.0240310 October 26, 2020 5 / 12
or negative linear relationship between viability and frozen storage time (p-values = 0.685 and
0.524 for trypan blue and flow cytometry assessed viabilities, respectively), with a poor represen-
tation of the data by the linear model (the adjusted square of the Pearson correlation coefficient,
adj. R-squared< 0). Similarly, when the water-free and wet thawing data were considered sepa-
rately no significant relationship was found: for water-free thawing the p-values were 0.944 and
0.631 for trypan blue and flow cytometry assessed viabilities, respectively, and for wet thawing,
the comparable p-values were 0.532 and 0.677, with negative adj. R-squared values.
Patient age and post-thaw survival
Patient age at the time of initial collection of blood for leukapheresis, ranging from 39 to 70 years
old, had no positive or negative relationship on the immediate post-thaw trypan blue viability
(p-value = 0.899) when considering the combined data from water-free and wet thawing (Fig
4A). The relationship determined by flow cytometry for post-thaw CD34+ viability (Fig 4B),
Fig 2. Bland-Altman analysis of the two different thawing methods. Plots of post-thaw viability, comparing wet and water free
thawing methods with line of equality for (A) CD45+ and (B) CD34+ post-thaw viabilities, determined through flow analysis.
https://doi.org/10.1371/journal.pone.0240310.g002
Fig 3. The comparative effect of cryogenic storage time of cryopreserved leukapheresis samples on the immediate
post-thaw cell viability. (A) Immediate post-thaw cell viability determined as trypan blue exclusion or (B) by flow
cytometry for CD34+ cells. Storage periods ranged between 3 months and 17 years, and results for water-free (WF)
and wet thawing are presented as open and filled symbols, respectively. The linear model applied to the data as a
function of cryogenic storage time is indicated by a dashed line. The adjusted square of the Pearson correlation
coefficient (adj. R-squared) indicating the extent of variability in the dataset explained by the linear model, is provided.
https://doi.org/10.1371/journal.pone.0240310.g003
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however, suggested a negative trend but this was not significant (p-value = 0.065). The linear
model explained only approximately 3% of the variability in the data (adj. R-squared = 0.0029).
When considering the data for water-free thawing, similar observations were made with p-values
of 0.970 and 0.065 for trypan blue and flow cytometry assessed viabilities, respectively. Similarly,
wet thawing gave no significant result for the trypan blue and flow cytometry assessments (p-val-
ues = 0.820 and 0.429 respectively, with negative adj. R-squared values; data not shown).
Patient gender and post-thaw survival
Post-thaw viability determined as trypan blue dye exclusion and by flow cytometry for CD45
+ and CD34+ cells are presented in Fig 5 together with trypan blue exclusion for all cells. The
mean viabilities are not statistically significant (p-value > 0.05) between male (n = 23) and
female (n = 15 trypan blue; n = 18 CD34+ and CD45+) patients, despite the apparent, higher
recovery for female patients.
Discussion
This study has shown that dry thawing is applicable to cellular materials such as leukapher-
esis samples, resulting in comparable, correlated, post-thaw outcomes to those produced by
an experienced operative using wet thawing (Figs 1 and 2). This was despite the longer time
taken to complete thawing in the water-free thawing system when compared to the conven-
tional water bath technique (means of 405 vs. 337 seconds respectively, p-value < 0.05).
This result may appear unexpected as, across the broader field of cryopreservation, rapid
thawing (at least as fast as can be achieved in a 37˚C water bath) is considered essential for
good post-thaw recovery for a very wide range of cell types [26–29]. However, recent stud-
ies have shown that rapid thawing at this level is not required for somatic mammalian cells
as long as the earlier cooling stage is appropriately controlled (as is the case with apheresis
samples). Damage on warming these samples is commonly caused by the expansion of
incomplete ice crystals as more energy becomes available for water mobility. While the
Fig 4. The effect of patient age at initial collection of leukapheresis samples before cryopreservation on immediate
post-thaw cell viability. (A) Immediate post-thaw cell viability determined as trypan blue exclusion or (B) by flow
cytometry for CD34+ cells. Results for water-free and wet thawing are presented as open and filled symbols,
respectively. Linear models applied to the combined water-free (WF) and wet thawing datasets as a function of patient
age are shown as dashed lines, and the adjusted square of their Pearson correlation coefficient (adj. R-squared)
indicating the percentage of variability in the dataset explained by the linear model, is indicated.
https://doi.org/10.1371/journal.pone.0240310.g004
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sample is still cold enough to support ice, water molecules will more readily migrate to the
surfaces of incomplete crystals to form more ice. Slow cooling, below about 10˚C min-1 in
DMSO-based cryoprotectants, allows complete ice formation on cooling and so largely
removes the requirement for rapid warming [6,11–13].
The rationale underlying rapid thawing can be illustrated by considering cryopreserved
sperm cells. In this instance rapid cooling is employed, together with a glycerol-based cryopro-
tectant. A consequence of this rapid cooling is that water loss from the cells is limited by diffu-
sion and so the amount of extracellular ice is less than would be expected if an equilibrium had
been reached. This means that ice can crystallise during thawing, as described above, causing a
potentially lethal osmotic shock for the cells [30]. Rapid thawing limits the extent of this ice for-
mation during thawing, so reducing any damaging, osmotic stresses. However, cryopreserved
apheresis samples represent a system with significantly different properties. The relatively slow
cooling rate and low viscosity, DMSO-based cryoprotectant that are employed allow more time
for diffusion and allow the maximum amount of ice to form during controlled cooling. Conse-
quently, ice crystallisation during thawing will be limited and so thawing can occur rapidly or
slowly with a minimal risk of osmotic stress. However, it is important that samples are either
used immediately or the DMSO washed out immediately after thawing. DMSO is toxic to cells
at higher temperatures, and so thawed cells left in an aqueous DMSO solution will be adversely
affected [31]. Establishing that water-free thawing is as effective as wet thawing is critical in
enacting GMP processes in the manufacture of cell therapies, as water-free thawing allows for
user-independent, traceable, and more accurately recordable thawing profiles, both for the
final cell therapy but also for early stages in the manufacture—e.g. thawing of an initial aphere-
sis sample which may be shipped cryopreserved to a manufacturing site as a starting material
for the treatment.
The data presented in Fig 3 indicates that extending frozen storage from 3 months to 17
years has no significant effect on the post-thaw outcome of the samples. To ensure the safe,
long-term storage of apheresis samples it is critical that the samples are held, continuously,
Fig 5. The comparative effect of patient gender on the immediate post-thaw viability of cryopreserved
leukapheresis samples. Cell viability was determined as trypan blue exclusion or by flow cytometry for CD45+ and
CD34+ cells. The p-values obtained from comparing means between patient gender are indicated.
https://doi.org/10.1371/journal.pone.0240310.g005
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below the glass transition temperature of the cryoprotectant solution, some -120˚C for
DMSO-based solutions [6,32]. Studies with other biological systems have shown this to be
effective, and necessary, for decades [4,33–37]. This is achieved as cellular, chemical and
biological processes in the sample effectively stop below this temperature [32]. Allowing
the storage conditions to rise above the glass transition temperature, even briefly, intro-
duces the risk of resumed diffusion, threatening the stability of the samples [38–40]. It
should also be noted that the trypan blue assay gave a higher level of viability than flow
cytometry in this instance, as was the case when assessing the effect of gender on post-that
performance (Fig 5). This assay is quick and inexpensive, and its use is commonplace, but
this potential overestimate of viability should be held in mind when calculating potential
cell numbers that can be transplanted.
Unwanted storage temperature fluctuations may occur where many samples are stored
together and retrieving one requires moving others, inadvertently exposing them to a temperature
rise. If this excursion goes above the glass transition temperature for any particular sample, then
a risk to stability arises. The few reports of decline in post-thaw outcome after storage in liquid
nitrogen vapour (below -120˚C) are likely due to such unintentional warming. Multiple tempera-
ture cycling between the vapour phase of liquid nitrogen and up to -120˚C has been shown to be
minimally damaging for PBMC cells [41], but similar studies for apheresis samples are lacking.
There was no significant negative impact of patient age on post-thaw assessment (Fig 4)
up to 70 years, the maximum within the study, which agrees with findings for healthy donors
[42]. This would appear to support continuing with the protocol, without modification, for
the greater proportion of the patient population. However, a possible trend was observed
for CD34+ cells where increased patient age seemed to negatively impact post-thaw viability
(Fig 4B), and it may be possible that this trend became significant if the dataset included
more patients aged 70 and above. Myeloma cases are more common in older patients with
an average age of 67 and reduced engraftment has been observed in patients of 70+ years,
particularly with respect to CD34+ cells [42,43]. This may become more significant concern
as survival rates improve and the upper age limit of the patient population increases. The
underlying reasons for this need to be determined and their significance for research into
possible changes in the cryopreservation protocol considered.
Patient gender also had no significant impact on the post-thaw outcome of cells. Few
studies have been reported looking specifically at the differences between male and female
cryopreservation outcome. From this study of peripheral blood mononuclear cells, any
improved outcome for female-derived samples did not stand up to statistical scrutiny.
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